Evidence map›Paper›PMID 37872494›Full record

ArticleBMC complementary medicine and therapies2023

Medicinal plant Miconia albicans synergizes with ampicillin and ciprofloxacin against multi-drug resistant Acinetobacter baumannii and Staphylococcus aureus.

Genilson Silva de Jesus, Danielle Silva Trentin, Thayná Fernandes Barros, Alda Maria Teixeira Ferreira, Bruna Castro de Barros, Patrícia de Oliveira Figueiredo, Fernanda Rodrigues Garcez, Érica Luiz Dos Santos, Ana Camila Micheletti, Nidia Cristiane Yoshida

Abstract read
In one paragraph

Article in BMC complementary medicine and therapies, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Genilson Silva de JesusLaboratório de Produtos Naturais Bioativos-PRONABio, Instituto de Química, Universidade Federal de Mato Grosso Do Sul, Campo Grande, Brazil.
Danielle Silva TrentinLaboratório de Bacteriologia & Modelos Experimentais Alternativos (BACMEA), Departamento de Ciências Básicas da Saúde, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil.
Thayná Fernandes BarrosLaboratório de Bacteriologia & Modelos Experimentais Alternativos (BACMEA), Departamento de Ciências Básicas da Saúde, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil.
Alda Maria Teixeira FerreiraInstituto de Biociências, Universidade Federal de Mato Grosso Do Sul, Campo Grande, Brazil.
Bruna Castro de BarrosInstituto de Biociências, Universidade Federal de Mato Grosso Do Sul, Campo Grande, Brazil.
Patrícia de Oliveira FigueiredoLaboratório de Produtos Naturais Bioativos-PRONABio, Instituto de Química, Universidade Federal de Mato Grosso Do Sul, Campo Grande, Brazil.
Fernanda Rodrigues GarcezLaboratório de Produtos Naturais Bioativos-PRONABio, Instituto de Química, Universidade Federal de Mato Grosso Do Sul, Campo Grande, Brazil.
Érica Luiz Dos SantosLaboratório de Produtos Naturais Bioativos-PRONABio, Instituto de Química, Universidade Federal de Mato Grosso Do Sul, Campo Grande, Brazil.
Ana Camila MichelettiLaboratório de Produtos Naturais Bioativos-PRONABio, Instituto de Química, Universidade Federal de Mato Grosso Do Sul, Campo Grande, Brazil. ana.micheletti@ufms.br.
Nidia Cristiane YoshidaLaboratório de Produtos Naturais Bioativos-PRONABio, Instituto de Química, Universidade Federal de Mato Grosso Do Sul, Campo Grande, Brazil. nidia.yoshida@ufms.br.

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001Fundação de Apoio ao Desenvolvimento do Ensino, Ciência e Tecnologia do Estado de Mato Grosso do Sul 308/2022
6 · The paper itself

Abstract

backgroundGiven the rising occurrence of antibiotic resistance due to the existence and ongoing development of resistant bacteria and phenotypes, the identification of new treatments and sources of antimicrobial agents is of utmost urgency. An important strategy for tackling bacterial resistance involves the utilization of drug combinations, and natural products derived from plants hold significant potential as a rich source of bioactive compounds that can act as effective adjuvants. This study, therefore, aimed to assess the antibacterial potential and the chemical composition of Miconia albicans, a Brazilian medicinal plant used to treat various diseases.

methodsEthanolic extracts from leaves and stems of M. albicans were obtained and subsequently partitioned to give the corresponding hexane, chloroform, ethyl acetate, and hydromethanolic phases. All extracts and phases had their chemical constitution investigated by HPLC-DAD-MS/MS and GC-MS and were assessed for their antibiofilm and antimicrobial efficacy against Staphylococcus aureus. Furthermore, their individual effects and synergistic potential in combination with antibiotics were examined against clinical strains of both S. aureus and Acinetobacter baumannii. In addition, 10 isolated compounds were obtained from the leaves phases and used for confirmation of the chemical profiles and for antibacterial assays.

resultsBased on the chemical profile analysis, 32 compounds were successfully or tentatively identified, including gallic and ellagic acid derivatives, flavonol glycosides, triterpenes and pheophorbides. Extracts and phases obtained from the medicinal plant M. albicans demonstrated synergistic effects when combined with the commercial antibiotics ampicillin and ciprofloxacin, against multi-drug resistant bacteria S. aureus and A. baumannii, restoring their antibacterial efficacy. Extracts and phases also exhibited antibiofilm property against S. aureus. Three key compounds commonly found in the samples, namely gallic acid, quercitrin, and corosolic acid, did not exhibit significant antibacterial activity when assessed individually or in combination with antibiotics against clinical bacterial strains.

conclusionsOur findings reveal that M. albicans exhibits remarkable adjuvant potential for enhancing the effectiveness of antimicrobial drugs against resistant bacteria.

Indexed as

Acinetobacter baumanniiAnti-Infective AgentsMelastomataceaePlants, MedicinalAmpicillinAnti-Bacterial AgentsBacteriaCiprofloxacinMicrobial Sensitivity TestsStaphylococcus aureusTandem Mass SpectrometryAmpicillinAnti-Bacterial AgentsAnti-Infective AgentsCiprofloxacinAntibiofilmAntibiotic resistanceBioactive natural productsMRSASecondary metaboliteSynergism

Identifiers

PMID37872494
PMCPMC10594757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.